Agoracom: Small Cap Investment - Resverlogix Corp. - Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

RVXoldtimer

Rank: President [?]

Points: 3190 [?]

Votes: 23 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

in response to

Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial

paladin

posted on Dec 22, 2020 09:35AM

paladin - the one big advantage is that Apabetalone has safety while the others are being administered with hope that there is no long term safety issues. They only have short term safety data.

3 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply